[COVID-19 vaccination: the reality after clinical trials]
- PMID: 33906339
- PMCID: PMC8638833
- DOI: 10.37201/req/035.2021
[COVID-19 vaccination: the reality after clinical trials]
Abstract
After the start of vaccination against SARS-CoV-2, enough clinical experience is already accumulating, in the real world and outside clinical trials, to resolve some of the questions that are still pending about this problem. The Scientific Committee on COVID-19 of the Madrid College of Physicians has discussed and reviewed some of these issues with a multidisciplinary approach. The following document is an attempt to answer some of these questions with the information available so far. This document is structured in questions on different aspects of the indications, efficacy and tolerance of anti-COVID-19 vaccination.
Tras el comienzo de la vacunación frente a SARS-CoV-2, se está acumulando ya suficiente experiencia clínica, en el mundo real y fuera de los ensayos clínicos, para resolver algunas de las cuestiones que siguen pendientes sobre este problema. El Comité Científico sobre COVID-19 del Colegio de Médicos de Madrid ha discutido y revisado algunos de estos temas con una aproximación multidisciplinar. El documento que sigue es un intento de responder a algunas de dichas cuestiones con la información disponible hasta el momento. Este documento se ha estructurado en preguntas sobre distintos aspectos de las indicaciones, eficacia y tolerancia de la vacunación anti-COVID-19.
Keywords: COVID-19; adverse events; indication; tolerance; vaccines.
©The Author 2021. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
References
-
- Hall V, Foulkes S, Charlett A, et al. Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study). England: June to November 2020 medRxiv 2021011321249642 doi: 10.1101/2021011321249642. - DOI
-
- Anónimo . Duration of immunity and reinfection following SARSCoV-2 infection [Internet], Dublín: reinfection-following-SARSCoV-2-infection.pdf.Health Information and Quality Authority (HIQA); 11 November 2020 [Consultado 5 Dic 2020] Disponible en: https://wwwhiqaie/sites/default/files/2020-11/Advice_Duration-of-immunit.... DOI:
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
